TY  - JOUR
AU  - Garcia-Manero, Guillermo
AU  - Santini, Valeria
AU  - Almeida, Antonio
AU  - Platzbecker, Uwe
AU  - Jonasova, Anna
AU  - Silverman, Lewis R
AU  - Falantes, Jose
AU  - Reda, Gianluigi
AU  - Buccisano, Francesco
AU  - Fenaux, Pierre
AU  - Buckstein, Rena
AU  - Diez Campelo, Maria
AU  - Larsen, Stephen
AU  - Valcarcel, David
AU  - Vyas, Paresh
AU  - Giai, Valentina
AU  - Olíva, Esther Natalie
AU  - Shortt, Jake
AU  - Niederwieser, Dietger
AU  - Mittelman, Moshe
AU  - Fianchi, Luana
AU  - La Torre, Ignazia
AU  - Zhong, Jianhua
AU  - Laille, Eric
AU  - Lopes de Menezes, Daniel
AU  - Skikne, Barry
AU  - Beach, C L
AU  - Giagounidis, Aristoteles
PY  - 2021
DO  - 10.1200/JCO.20.02619
UR  - http://hdl.handle.net/10668/17400
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - Treatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating agent, in patients with International Prognostic Scoring...
LA  - en
KW  - Administration, Oral
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Azacitidine
KW  - Female
KW  - Follow-Up Studies
KW  - Humans
KW  - Male
KW  - Middle Aged
KW  - Myelodysplastic Syndromes
KW  - Prognosis
KW  - Prospective Studies
KW  - Survival Rate
TI  - Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.
TY  - research article
VL  - 39
ER  -